

# ASX ANNOUNCEMENT

3 November 2023

## CLEANSING NOTICE UNDER SECTION 708A(5)(e)

On 2 November 2023, Anteris Technologies Ltd (ASX: AVR) (**Anteris** or the **Company**) issued 1,539,150 new fully paid Ordinary Shares (**New Shares**) to various sophisticated and professional investors at an issue price of \$20.00 per new share, raising \$30,783,000 before issue costs.

### Details of the securities issued

|                                    |                            |
|------------------------------------|----------------------------|
| Class of securities:               | Fully paid ordinary shares |
| ASX code:                          | AVR                        |
| Date of the issue:                 | 2 November 2023            |
| Total number of securities issued: | 1,539,150                  |

Anteris gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (the **Corporations Act**) that:

1. the New Shares have been issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
  - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (b) section 674 of the Corporations Act;
3. as at the date of this notice, there is no 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by Anteris under section 708A(6)(e) of the Corporations Act.

**ENDS**



## About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company's lead product, DurAVR™, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR™ THV was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR™ THV is made using ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 50,000 patients worldwide.

The ComASUR™ Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR™ THV with balloon-expandable delivery, allowing precise alignment with the heart's native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

## Authorisation and Additional information

This announcement was authorised by Mr Stephen Denaro, Company Secretary.

### For more information:

#### Investor Relations (US)

Malini Chatterjee, Ph.D.  
Managing Director  
Blueprint Life Science Group  
+1 917 330 4269

#### Investor Relations

investors@anteristech.com  
Anteris Technologies Ltd  
+61 1300 550 310 | +61 7 3152 3200

[www.anteristech.com](http://www.anteristech.com)

Twitter: @AnterisTech

Facebook: [www.facebook.com/AnterisTech](https://www.facebook.com/AnterisTech)

LinkedIn: <https://www.linkedin.com/company/anteristech>

